
|Videos|January 18, 2023
Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy
Author(s)Stephen J. Freedland, MD
Dr Stephen J. Freedland reviews the available treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC), visceral disease, and no actionable genomic alterations, who received prior treatment with docetaxel and AR-targeted therapy.
Advertisement
Episodes in this series

Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Permanent J code for mitomycin for intravesical solution now in effect
2
GPS-ProtecT study launched to validate Genomic Prostate Score in active surveillance
3
Real-World Evidence in mCSPC Management
4
Pearls & Perspectives: Sexual Health at the Intersection of Urology and Therapy, with Nicoletta Heidegger, MA, MEd, LMFT
5




















